+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AK112, a PD-1VEGF bispecific antibody, as a consolidation treatment for patients with limited stage small cell lung cancer who have not shown disease progression after concurrent chemoradiation therapy. This phase III, randomized, double-blind study aims to compare the effectiveness and safety of AK112 against a placebo in this specific patient group. Participants will receive either AK112 or a placebo intravenously every three weeks as consolidation therapy following their initial chemoradiation. The study includes two groups one receiving AK112 at a dose of 20 mgkg every three weeks, and the other receiving a matching placebo on the same schedule. Treatment continues under close monitoring to assess outcomes. Throughout the study, participants will undergo regular assessments including scans and evaluations to monitor progression-free survival and overall survival over approximately six years. Additional outcome measures include response rates and disease control rates assessed by both independent review and investigators, along with safety monitoring for adverse events. This long-term follow-up helps researchers understand how the treatments perform and their impact on patient health.

Age: 18Years +All GendersPhase 3
53 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the AGENT Drug-Coated Balloon DCB compared to standard percutaneous coronary intervention PCI treatments like drug-eluting stents DES and balloon angioplasty in patients with new de novo coronary artery lesions. This open-label, randomized controlled study includes a pharmacokinetic sub-study and an intravascular ultrasound sub-study to provide additional insights. Participants will be randomly assigned to receive either the AGENT DCB or standard care, which may include drug-eluting stents or balloon angioplasty. The study covers different lesion types such as small vessel, bifurcation with side branches, and long lesions, with treatments tailored accordingly. The procedures are performed as part of PCI, and treatment allocation is done in parallel groups. During the trial, participants will undergo follow-up evaluations to monitor lesion outcomes and safety, including assessments up to 12 months after the procedure. Researchers will measure the rate of target lesion failure at 12 months as the primary outcome. Participants will also be monitored for adherence to protocol and any adverse events, with the overall study lasting until March 2032.

Age: 18Years +All GendersPhase Not Applicable
71 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of BAT5906 compared to Lucentis in people with diabetic macular edema DME. This multicenter, randomized, double-blind trial plans to enroll 406 participants aged 18 to 80 years who have DME affecting the central part of the retina. The primary goal is to assess changes in best-corrected visual acuity BCVA from the start of the study to week 52 using the ETDRS chart. Participants are randomly assigned to receive either BAT5906 or Lucentis through intravitreal injections directly into the eye. Each treatment is given once every 4 weeks for three doses, followed by monitoring visits every 4 weeks with possible additional doses as needed, continuing through week 52. BAT5906 is administered at 4.0 mg per eye, while Lucentis is given at 0.5 mg per eye. Throughout the study, participants undergo regular eye exams, safety assessments, and blood tests to monitor immune response. Researchers measure visual acuity changes to determine treatment effects. The study includes ongoing safety monitoring and assessments until week 52 to evaluate both treatments effectiveness and safety in managing DME.

Age: 18Years - 80YearsAll GendersPhase 3
50 locations
E

Actively Recruiting

Bladder cancer is a common urinary system cancer, with 70-80% being nonmuscle invasive types treated primarily by transurethral resection of bladder tumor TURBT. This study evaluates the effects of remimazolam, a new benzodiazepine with rapid onset and short action, on emergency delirium and cancer recurrence after bladder cancer surgery. Researchers are interested in comparing remimazolam to propofol anesthesia and understanding its impact on postoperative delirium and long-term cancer outcomes. Participants are randomly assigned to receive either remimazolam or propofol intravenously for anesthesia induction and maintenance during bladder tumor surgery. The anesthesia dose is adjusted to maintain a specific brain activity level Bispectral Index between 40 and 60. Pain relief and muscle relaxation are provided with other medications, and inhaled sevoflurane may be given if needed. Both groups receive similar supportive drugs to manage pain and muscle relaxation. During the study, patients are closely monitored for early emergence delirium within 2 hours post-surgery and for recurrence-free survival up to 3 years. Other outcomes include postoperative delirium, nausea, awareness during surgery, hospital stay length, complications, and survival rates. Assessments include clinical evaluations in the recovery unit and follow-up visits over several years to measure cancer recurrence and quality of life.

Age: 50Years - 90YearsAll GendersPhase 4
6 locations
C

Actively Recruiting

Researchers are studying fibromyalgia FM, a chronic pain condition marked by widespread pain, fatigue, and emotional challenges. The trial aims to compare the effects and safety of pregabalin alone versus pregabalin combined with venlafaxine, hypothesizing that the combination may provide better pain relief without more side effects. The study is a randomized, multicenter clinical trial focused on treatment outcomes for adults with FM. Participants will be assigned to one of two groups one receiving pregabalin alone and the other receiving pregabalin with venlafaxine. Pregabalin treatment starts at 150 mgday and may increase to 450 mgday based on response. Venlafaxine begins at 75 mgday with possible weekly increases up to 225 mgday if tolerated. Treatment doses are adjusted individually over the study period. During the 12-week trial, participants will regularly report their pain levels, including average and worst pain intensity, at weeks 1, 2, 4, 8, and 12. Researchers will also assess functional impact, sleep quality, mood, medication doses, and any adverse events. These ongoing evaluations help monitor treatment effects and safety throughout the study duration.

Age: 18Years +All GendersPhase Not Applicable
2 locations
W

Actively Recruiting

Researchers are studying the safety and activity of weekly irinotecan liposome injections in patients with relapsed and metastatic Ewing Sarcoma, a condition with poor prognosis after standard therapy. This phase 1 dose-finding study uses a Bayesian Optimal Interval design to explore treatment in patients who have failed first-line chemotherapy including doxorubicin, vincristine, cyclophosphamide, ifosfamide, and etoposide. Participants receive Irinotecan Hydrochloride Liposome Injection weekly, with 5 doses administered every 6 weeks. This liposomal form may stay longer in the body and offers a more convenient weekly schedule compared to traditional irinotecan infusion. Both pediatric and adult patients are included, with treatment tailored to their condition and monitored closely. During the study, participants undergo regular assessments including CT or MRI scans to measure tumor response by RECIST 1.1 criteria. Researchers will monitor the maximum tolerated dose over 6 weeks and track response rates and progression-free survival up to 24 months. Safety evaluations and organ function tests are conducted throughout, with follow-up visits scheduled to observe treatment effects and tolerability.

Age: 8Years - 40YearsAll GendersPhase 1
3 locations